Veracyte Inc (NASDAQ:VCYT): Institutional Investor Sentiment Down to 1.04

June 18, 2018 - By Nellie Frank

Veracyte, Inc. (NASDAQ:VCYT) Logo

Sentiment for Veracyte Inc (NASDAQ:VCYT)

Veracyte Inc (NASDAQ:VCYT) institutional sentiment decreased to 1.04 in 2018 Q1. Its down -0.19, from 1.23 in 2017Q4. The ratio worsened, as 29 investment professionals increased and opened new equity positions, while 28 cut down and sold positions in Veracyte Inc. The investment professionals in our partner’s database now own: 20.91 million shares, down from 21.45 million shares in 2017Q4. Also, the number of investment professionals holding Veracyte Inc in their top 10 equity positions was flat from 2 to 2 for the same number . Sold All: 4 Reduced: 24 Increased: 18 New Position: 11.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $295.03 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

The stock decreased 3.05% or $0.27 during the last trading session, reaching $8.59. About 73,358 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has declined 6.02% since June 18, 2017 and is downtrending. It has underperformed by 18.59% the S&P500.

Analysts await Veracyte, Inc. (NASDAQ:VCYT) to report earnings on July, 30. They expect $-0.27 earnings per share, down 22.73 % or $0.05 from last year’s $-0.22 per share. After $-0.27 actual earnings per share reported by Veracyte, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Cannell Capital Llc holds 3.68% of its portfolio in Veracyte, Inc. for 2.06 million shares. Acuta Capital Partners Llc owns 3.32 million shares or 3.01% of their US portfolio. Moreover, First Light Asset Management Llc has 1.04% invested in the company for 849,566 shares. The Massachusetts-based Eventide Asset Management Llc has invested 0.56% in the stock. Broadfin Capital Llc, a New York-based fund reported 600,658 shares.

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $96,049 activity.

More news for Veracyte, Inc. (NASDAQ:VCYT) were recently published by:, which released: “Veracyte (VCYT) Says New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly …” on May 23, 2018.‘s article titled: “Veracyte to Present at the William Blair 38” and published on May 23, 2018 is yet another important article.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: